Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02864992 · ClinicalTrials.gov registry record · Phase 2
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
A Phase 2 study of Lung Adenocarcinoma Stage IIIB/IV and Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, sponsored by EMD Serono Research & Development Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 337
- Enrollment target
- 20
- Study locations
NCT02864992 is a Phase 2 study of Lung Adenocarcinoma Stage IIIB/IV and Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification that is active but no longer recruiting, run by EMD Serono Research & Development Institute. The registered enrollment target is 337 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT02864992, a Phase 2 study of Lung Adenocarcinoma Stage IIIB/IV and Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, is active but no longer recruiting, sponsored by EMD Serono Research & Development Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 337 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Conditions Studied
Interventions
- DRUG Tepotinib
Study Locations (20)
California
- City of Hope Cancer Center - Duarte
- California Cancer Associates for Research & Excellence, Inc. - Encinitas
- St. Joseph Hospital - Orange
- Torrance Health Association - Redondo Beach
- St Joseph Heritage Healthcare - Santa Rosa
Missouri
- St. Louis Cancer Care, LLP - Bridgeton
- Saint Louis University Cancer Center - St Louis
- Saint Louis University - St Louis
Florida
- Holy Cross Hospital Inc. - Fort Lauderdale
- H. Lee Moffitt Cancer Center and Research Institute, Inc - Tampa
Georgia
- University Cancer & Blood Center, LLC - Athens
- Winship Cancer Institute - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
- Ingalls Hospital - Harvey
New Jersey
- Summit Medical Group, P.A. - Berkeley Heights
- Summit Medical Group - Berkeley Heights
Colorado
- Rocky Mountain Cancer Centers, LLP - Denver
Indiana
- Community Regional Cancer Care - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02864992
The ClinicalTrials.gov registry entry for NCT02864992 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 337 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Adenocarcinoma Stage IIIB/IV appearing as the primary indexed condition, and to 1 intervention - of which Tepotinib is the first listed.
NCT02864992 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT02864992 about?
NCT02864992 is a clinical study titled "Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)". This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality...
What is the current status of trial NCT02864992?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 337 participants. The study started on 2016-09-13. Estimated completion is 2026-04-30.
What conditions does trial NCT02864992 study?
This clinical trial studies the following conditions: Lung Adenocarcinoma Stage IIIB/IV, Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification.
What interventions are being tested in trial NCT02864992?
The interventions under investigation include: Tepotinib (DRUG).
Who is sponsoring clinical trial NCT02864992?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02864992 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Adenocarcinoma Stage IIIB/IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Lung Adenocarcinoma Stage IIIB/IV
All registered trials for this condition
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.